Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1904

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 14
Chunk 1904
---

  
    Research and development1 
    $2,212,000  
    $2,520,000 
  
    General and administrative2 
    $3,243,000  
    $3,903,000 
  
    Cash used in operating activities3 
    $7,646,000  
    $10,130,000 

  1
  Research
  and development expenses consist primarily of costs related to laboratory operations, clinical trial execution, investigational
  device testing, design iterations, and personnel-related expenses associated with research activities. These costs are not confined
  to a single financial statement line item and may be classified within general and administrative expense, professional fees, or
  payroll, depending on their nature. These expenses are regularly reviewed by the CODM as a single category for internal
  decision-making purposes.

  2
  General and administrative expense includes overhead, clinical trial-related administrative and planning costs, and manufacturing-related
costs such as raw materials. These are not separately reviewed by the CODM and are assessed as part of the broader G&A category for
decision-making purposes.

  3
  Cash used in operating activities is a key metric monitored by the CODM in evaluating resource needs, development pacing, and investment
feasibility in the absence of revenue.

     F-25 

The Company does not allocate assets by segment, and the CODM does
not use a measure of segment profit or loss to evaluate performance. There were no changes to the internal reports provided to or reviewed
by the CODM during the years presented.

Entity-Wide Information:

·The
Company did not recognize revenue during the fiscal year ended March 31, 2025.
·All
long-lived assets are located in the United States.
·A
significant portion of clinical trial activity is conducted through the Company’s wholly owned subsidiary based in Australia.

10. SUBSEQUENT EVENTS

On June 25, 2025, the Company
received notice from Nasdaq stating the Company has regained compliance with Listing Rule 5550(a)(2), and that the matter is now
closed.

Reverse
Split – Following the approval of a reverse stock split at a Special Meeting of Stockholders on May 13, 2025, our Board of Directors
approved a 1-for-8 reverse stock split or our outstanding shares of Common Stock, effective as of the close of business on June 6, 2025
with an effective trading date of June